RCC Samples With Higher Entropy Associated With Favorable Prognosis

Share this content:
Renal cell carcinoma samples with higher entropy, a measure of evenness and diversity, were associated with favorable prognosis.
Renal cell carcinoma samples with higher entropy, a measure of evenness and diversity, were associated with favorable prognosis.

Renal cell carcinoma (RCC) samples with higher entropy, a measure of evenness and diversity, were associated with favorable prognosis, a study presented at the 2016 Genitourinary Cancers Symposium in San Francisco, CA has shown.1

Because previous research has demonstrated an inverse association between suppression of immune surveillance mechanisms and activation of the vascular endothelial growth factor receptor (VEGFR) pathway, suggesting that T-cell repertoires may affect response to VEGFR inhibition, researchers sought to evaluate the association between T cell repertoire and clinical outcomes in patients with RCC receiving frontline pazopanib.

For the study, researchers analyzed pre-treatment RCC tumors from a phase 3 study of patients with metastatic RCC who were randomly assigned to receive pazopanib 800 mg daily or placebo for TCR gamma (TCRG) and TCR beta (TCRB) CDR3 regions. TCR clonality, a measure of total repertoire represented by expanded clones, and entropy were assessed, as well as programmed death-ligand 1 (PD-L1) expression levels.

Results showed that TCRB and TCRG entropy were highly correlated, and placebo-treated samples with higher TCRG entropy were associated with improved median progression-free survival compared with those with lower TCRG entropy (12.8 months vs 3.1 months; P = .023). Researchers observed a similar trend for samples with TCRB entropy.

In contrast, researchers found no association between entropy or clonality and maximal reduction in tumor volume or PD-L1 expression levels.

“Identification of tumors with restricted TCRB/G chain usage and less diverse repertoire, as represented by lower entropy and higher clonality, may impact responses to VEGFR blockade and requires further study,” the authors concluded.

Reference

Ho TH, Gagnon RC, Liu Y, et al. T-cell receptor (TCR) repertoire in metastatic renal cell carcinoma (RCC) patients treated with first-line vascular endothelial growth factor receptor blockade. J Clin Oncol. 2016; 34 (suppl 2S; abstr 501).

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters